IBA (Ion Beam Applications SA), a Belgium-based provider of proton therapy solutions for the treatment of cancer, has received FDA clearance for its new super conducting accelerator. The accelerator is the latest development, essential to the ProteusONE, IBA’s compact intensity-modulated proton therapy (IMPT) solution, that required approval from regulatory authorities.
The FDA clearance makes ProteusONE, the only compact proton therapy solution that is certified to treat patients in the U.S. with optimized pencil beam scanning (PBS) and image guidance.
IBA has already signed 13 contracts to provide its compact proton therapy solution, ProteusONE, worldwide. As stated in a company news release, the recent FDA clearance is an important milestone that will ensure on time delivery of all of IBA’s current and future contracts and underscores the fact that for compact proton therapy, IBA has the fastest delivery and installation times in the world.
“FDA clearance of our ProteusONE’s new super conducting accelerator will be a significant market accelerator for proton therapy in the United States, because ProteusONE provides the most advanced treatment mode (IMPT) within the most compact and affordable system,” shares Beth Klein, president of IBA Proton Therapy North America. “Any hospital considering proton therapy can now afford it through the Proteus One’s lower capital and operating costs without making any clinical compromise. Ultimately, this will make proton therapy more accessible to the radiation therapy patients in the United States who can benefit from it.
The ProteusONE is the only FDA-cleared and CE-marked compact solution that uses image-guided IMPT. With IBA’s industrialized production together with a complete CE approval and FDA clearance, IBA is now able to install complete proton therapy system in less than 12 months.Back To Top
IBA's new generation accelerator receives FDA clearance . Appl Rad Oncol.